News

Online survey results show adults with psoriasis in specific areas may be treating and monitoring disease without clinician guidance—sometimes out of embarassment.

Long-term, real-world data show the IL-23 inhibitor benefits patient-reported measures of psychological wellbeing.

New data show adults receiving the biologic for eczema may see improvements in sleep disturbance within 4 weeks.

Post hoc analysis data from JADE REGIMEN show continuous and reduced-dose regimens provided similar efficacy and safety outcomes in the 2 age groups.

An interview with Dr. Katta on her SDPA 2022 presentation, in which she covers the topic of obesity and its relationship to skin conditions such as plaque psoriasis.

In one of his SDPA 2022 presentations, Dr. Rosen spoke on different dermatological conditions with vitiligo-like presentations.

Phase 3 data suggest the novel twice-daily drug provides favorable efficacy and consistent safety over a regular regimen in patients aged 12 years and older.

Phase 3 data suggest children aged <6 months to 5 years old have benefit in itch relief and skin clearance as soon as 1 week into systemic therapy regimens.

During her SDPA 2022 presentation, Cynthia Trickett explored the topic of psoriasis, including comorbidities and treatment options.

New data from ECZTRA 1 and 2 show patients unable to achieve complete skin clearance nonetheless benefitted in at least 1 component of disease improvement.

For safety, 24.1% of the entire study population experienced adverse events, with 18 participants developing tuberculosis.

An interview on several major highlights from Dr. Orozsco’s presentation about the greater visibility and importance of physician associates at SDPA 2022.

An interview with Dr. Orozco regarding her presentation at SDPA 2022 on the topic of physician associates and their value in the modern medical system.

Serious forms of cardiovascular diseases were observed to be connected to a specific form of AMD with subretinal drusenoid deposits.

There was a similar prevalence of NAFLD in patients who were overweight as there was for individuals who were obese.

An SDPA 2022 interview with Dr. Robert Kirsner regarding his presentation regarding the topic of wound healing and related changes in the field.

In this special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, break down what the approval of teplizumab means for type 1 diabetes. During the episode, hosts take a deep dive into type 1 diabetes staging and hypothesize around the role of CDCES in educating primary care and other specialties to optimize the potential of teplizumab.

On November 17, the US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.

An interview at the SDPA 2022 Conference on major talking points from Dr. Robert Kirsner’s presentation on wound care with dermatologists and physician associates.

The novel investigational complement C5 inhibitor is the only product for treatment of geographic atrophy to achieve two positive phase 3 pivotal trials with statistical significance.

The mean daily adherence was higher in the mDOT group compared to the patient navigation group.

An interview from SDPA 2022 regarding highlights from Dr. Robert Kirsner’s presentation on dermatologists and wound healing.

A study published in Diabetologia discovered that individuals who are exposed to high light pollution while they sleep show a greater risk of developing type 2 diabetes.

The apolipoprotein E ε2/ε3/ε4 variant was associated with a significant linearly increasing trend for risk of AMD from ε4 to ε3 to ε2.

Insulin glargline-aglr is the second approved interchangeable biosimilar insulin product to insulin glargine indicated to improve glycemic control in patients with diabetes mellitus.

The results show serum IgA-IgG immune complex levels decreased in both patients treated with atacicept 25 mg ab atacicept 75 mg over time.

Ardelyx was issued a Complete Response Letter in July requestion an additional trial.

Patients with psoriasis in high-impact areas may benefit from either of 2 available dosing regimens of the biologic.